ImmunoPrecise Antibodies Ltd. (IPA)
$4.62-7.04%Close
SELLCRISIS · day 1
Key stats
- Market cap
- $213M
- Beta
- 0.49
- P/E (TTM)
- -8.15
- 1W
- -7.41%
- 1M
- -11.83%
- vs SPY 1W
- -7.28%
- vs SPY 1M
- -14.34%
Industry peers
FMP comparable companies · ranked by market cap
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
FUNDAMENTALS
[SCORES & PROFILE]
- FUND
- 17
- VALUE
- 10
- GROWTH
- 32
- GARP
- 8
- TYPE
- Balanced
Composite of Value · Growth · GARP
ROIC-38.0%
REV YoY-
ROE-63.4%
EPS YoY-
ROA-52.7%
GROSS60
OP-65
NET-66
[VALUATION]
P/E TTM-8.15
P/E FWD-
SECTOR PE20.48
INDUSTRY PE13.99
P/B7.15
P/FCF-
EV/EBITDA-9.38
EV/EBIT-
PEG-
FCF YIELD-
RISK
INT COV-
D/E23.71
ALTMAN Z-
CURR RATIO3.74
ND/EBITDA-
BETA0.49
Company news
FAQ
- What is LOPJLB’s current signal on IPA?
- LOPJLB’s latest quantitative signal on ImmunoPrecise Antibodies Ltd. (IPA) is SELL in a CRISIS regime. Signals are updated daily.
- What market regime is IPA in?
- ImmunoPrecise Antibodies Ltd. (IPA) is currently classified in the CRISIS HMM market regime on LOPJLB.
- What does ImmunoPrecise Antibodies Ltd. (IPA) do?
- ImmunoPrecise Antibodies Ltd. (IPA) is a global biotechnology firm that, through its subsidiaries, focuses on the development and production of antibodies, alongside offering a broad spectrum of related scientific services. Its operational footprint spans across the United States, Canada, Europe, Australia, and other international territories. For the research community, IPA delivers a diverse …